BlossomHill Therapeutics, Inc.(BLSM)

Biotechnology · San Diego, CA

$17.91-2.03 (-10.18%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:50:42.226Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:50:42.226Z.

Quote observation: 2026-10-06T18:50:07.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 520,843,571
Total debt · period ending 2026-06-30: 23,371,000
Cash · period ending 2026-06-30: 95,376,000
TTM operating income · period ending 2026-06-30: N/A

FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BLSM EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

BLSM Competitors' EV/EBIT Ratio

BLSM

BlossomHill Therapeutics, Inc.

Current

Market Cap

$520.84M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs BLSM

Market Cap

$523.62M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs BLSM

Market Cap

$520.25M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs BLSM

Market Cap

$520.22M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PHAT

Phathom Pharmaceuticals, Inc.

vs BLSM

Market Cap

$535.16M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBIO

Crescent Biopharma, Inc.

vs BLSM

Market Cap

$513.70M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PROK

ProKidney Corp.

vs BLSM

Market Cap

$536.32M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NVCT

Nuvectis Pharma, Inc.

vs BLSM

Market Cap

$534.18M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs BLSM

Market Cap

$535.63M

EV/EBIT Ratio

N/A

TTM Avg

189.50x

3Y Avg

189.50x

5Y Avg

189.50x

MASS

908 Devices Inc.

vs BLSM

Market Cap

$510.17M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
BlossomHill Therapeutics, Inc. (BLSM)	$520.84M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$523.62M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$520.25M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$520.22M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$535.16M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$513.70M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$536.32M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$534.18M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$535.63M	N/A	189.50x	189.50x	189.50x
908 Devices Inc. (MASS)vs ›	$510.17M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

BLSM EV/EBIT Ratio Metrics

BLSM Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics